KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Asset Writedowns and Impairment (2023 - 2025)

Historic Asset Writedowns and Impairment for Biomarin Pharmaceutical (BMRN) over the last 6 years, with Q1 2025 value amounting to $3.0 million.

  • Biomarin Pharmaceutical's Asset Writedowns and Impairment changed N/A to $3.0 million in Q1 2025 from the same period last year, while for Sep 2025 it was $3.0 million, marking a year-over-year decrease of 9352.85%. This contributed to the annual value of $19.9 million for FY2024, which is 4848.48% down from last year.
  • As of Q1 2025, Biomarin Pharmaceutical's Asset Writedowns and Impairment stood at $3.0 million.
  • In the past 5 years, Biomarin Pharmaceutical's Asset Writedowns and Impairment ranged from a high of $26.0 million in Q4 2023 and a low of $3.0 million during Q1 2025
  • Moreover, its 3-year median value for Asset Writedowns and Impairment was $12.6 million (2023), whereas its average is $12.3 million.